Despite receiving 4 doses.. Pfizer CEO has contracted coronavirus for the second time

Despite receiving 4 doses.. Pfizer CEO has contracted coronavirus for the second time

Pfizer CEO Albert Bourla announced on Saturday that tests had tested positive for COVID-19, despite receiving 4 doses of the company's anti-virus vaccine.

"I feel good and I don't have any symptoms," Bourla said.

• Pfizer's 60-year-old CEO has contracted COVID-19

• In August he began treatment with his company's BAXLOVID drug.

• Received four doses of coronavirus vaccine

• created by Pfizer and its German business associate Biontech.

The chief executive said he had not yet taken the activated dose of the new bi-parity vaccine.

The doses of the dual-parity vaccine, developed by Moderna and the Pfizer and Piontech team, are aimed at confronting the subtractors of Omicron, "B. Eh. 4 "and" B. " Eh. 5".

Bourla said he had not yet received that dose "because he had been following the guidelines of the Centers for Disease Control and Prevention to wait three months since the previous COVID infection in mid-August.

Study: Biontech/Pfizer enhanced dose efficacy decreased after 3 months

How long does vaccination with a third dose of the Pyontech/Pfizer vaccine protect against a severe trajectory of Delta and Omicron mutants?

 The result of a study suggests that additional vaccine doses may be necessary, at least in the elderly.

The high level of protection against severe coronavirus-mutated trajectory "Omicron" is initially shrinking a few months after receiving an enhanced dose of the Pyontech/Pfizer vaccine, according to the results of a new study funded by Pfizer, published in The Lancet Respiratory Medicine, according to a report on the website of Deer Spiegel.

Researchers analyzed more than 11 thousand hospitalizations and emergency admissions due to acute respiratory infections. 

In the study period from December 2021 to February 2022, both the "Delta" and "Omicron" interlocutors were widespread.

Conclusions and recommendations

The study results: After three doses, the efficacy of the Biontech/Pfizer vaccine against hospitalizations due to omycron infection was 85% less than three months later, falling to 55% after three months or more.

 With regard to admission to emergency rooms, the rate of protection against Omycron after receiving three doses was 77% after less than three months, and fell to 53% after three months or more.

The study's main stomach, epidemiologist Sarah Tratov, wrote :

 "Enhanced Biontech/Pfizer doses significantly improve protection against the omycron mutant, although this protection against emergency admissions and hospitals appears to diminish after three months", explaining in contrast that some of the efficacy provided by the enhanced dose remains even after this period.

For Delta, trends in low effectiveness against coronavirus were generally similar, yet the effectiveness was estimated to be higher than for Omicron at all times.

On average, the efficacy of the Biontech/Pfizer vaccine against Omicron was significantly higher after three doses after two doses.

In Germany, the Standing Committee on Vaccination currently recommends a second enhanced dose for persons over 70 years of age and for persons with a disease history.

 German Health Minister Karl Lauterbach recently called in Brussels for a fourth-dose vaccination for all people over the age of 60.

In early April, the European Union Medicines Agency "EMA" announced that a fourth dose for all citizens was currently unnecessary, but noted that a fourth dose could be feasible for people over 80, given the high risk of a severe coronavirus trajectory.